Biopharmaceutical manufacturer.
Policy issues relating the U.S.-China Joint Commission on Commerce and Trade, including Article 26.3 of Chinese Patent Law and biopharmaceutical intellectual property. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program; policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act"; H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act"; and policy issues relating to orphan drugs and medicines for rare diseases.
TRD - Trade (domestic/foreign) HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
FERGUSON STRATEGIES, LLC
801 Pennsylvania Ave NW, Suite 230, Washington, DC, 20004-2697, US
CHRIS JONES ADAM HIGGINS CHRIS JONES ADAM HIGGINS